[Tree] Leqembi approved for Alzheimer's treatment in Hong Kong

Version 0.28 (2024-07-11 03:32:16.255000)

updates: Leqembi approved for the treatment of Alzheimer's disease in Hong Kong

  • ➔
Version 0.27 (2024-06-25 07:58:57.521000)

updates: AstraZeneca's Imfinzi fails Phase III trial for early-stage lung cancer

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
Version 0.26 (2024-05-30 19:33:14.907000)

updates: Ivonescimab's success in Phase III trial for NSCLC

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
Version 0.25 (2024-05-29 08:45:05.954000)

updates: Incorporated information about Owkin's precision AI drug pipeline in oncology and immunology

  • ➔
  • ➔
  • ➔
  • ➔
Version 0.24 (2024-05-27 18:09:49.802000)

updates: Added information about Parkinson's Disease pipeline analysis

  • ➔
  • ➔
  • ➔
Version 0.23 (2024-05-23 08:01:56.182000)

updates: Incorporation of information about Owkin's precision AI drug pipeline in oncology and immunology

  • ➔
  • ➔
Version 0.22 (2024-05-17 23:28:40.819000)

updates: Incyte collaborates with China Medical System for povorcitinib, Cybin to present at healthcare company showcase

  • ➔
Version 0.21 (2024-04-05 20:36:55.030000)

updates: Incyte signs collaboration and license agreement with China Medical System for povorcitinib

  • ➔
Version 0.2 (2024-03-28 00:16:14.818000)

updates: New drug Savolitinib sNDA accepted in China for MET Exon 14 NSCLC

  • ➔
Version 0.19 (2024-03-22 14:25:28.362000)

updates: Shuttle Pharma receives FDA approval for Phase 2 Clinical Trial of Ropidoxuridine for glioblastoma treatment

  • ➔
Version 0.18 (2024-03-15 12:51:41.663000)

updates: The first two patients have been dosed in the Phase 1 clinical trial for AI-guided drug candidate, LP-284

  • ➔
Version 0.17 (2024-03-07 07:55:51.222000)

updates: Luye Pharma launches innovative drug for Small Cell Lung Cancer in Hong Kong and Macao

  • ➔
Version 0.16 (2024-02-27 12:05:34.863000)

updates: Nuvalent's NVL-520 receives breakthrough therapy designation for ROS1-positive lung cancer

  • ➔
Version 0.15 (2024-02-27 12:05:00.030000)

updates: FDA grants breakthrough status to Nuvalent's lung cancer drug

  • ➔
Version 0.14 (2024-02-16 15:50:30.585000)

updates: Russia's potential breakthrough in cancer vaccines

  • ➔
Version 0.13 (2024-02-15 13:02:46.152000)

updates: Inclusion of Russia's potential breakthrough in cancer vaccines

  • ➔
  • ➔
  • ➔
Version 0.12 (2024-01-31 15:36:41.187000)

updates: New breakthrough in mRNA therapy and development of room-temperature mRNA delivery system

  • ➔
  • ➔
Version 0.11 (2024-01-29 13:44:25.053000)

updates: Breast cancer vaccine trials show promising results

  • ➔
Version 0.1 (2024-01-29 13:44:01.463000)

updates: Addition of information about a clinical trial for a bowel cancer vaccine

  • ➔
Version 0.09 (2024-01-22 14:11:18.707000)

updates: Addition of information about programmable mRNA therapy for cancer treatment

  • ➔
Version 0.08 (2023-12-28 17:43:53.237000)

updates: Scientists develop groundbreaking method using vibrating molecules

  • ➔
Version 0.07 (2023-12-28 03:01:07.198000)

updates: New information about the effectiveness of Moderna's mRNA cancer vaccine and the discovery of 'molecular jackhammers' to combat cancer cells

  • ➔
  • ➔
  • ➔
  • ➔
Version 0.06 (2023-12-28 03:00:42.008000)

updates: Inclusion of new breakthrough using 'molecular jackhammers' activated by near-infrared light to destroy cancer cells and eliminate the need for surgery

  • ➔
  • ➔
  • ➔
Version 0.05 (2023-12-28 03:00:15.879000)

updates: Integration of a new breakthrough in cancer treatment using vibrating molecules

  • ➔
  • ➔
Version 0.04 (2023-12-27 07:15:16.801000)

updates: New information on Moderna's mRNA cancer vaccine

  • ➔
Version 0.03 (2023-12-22 12:11:36.843000)

updates: Breakthrough method for tracking cellular changes over time

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
Version 0.02 (2023-12-18 08:25:31.380000)

updates: Immunotherapy drugs show promise in blocking tumor progression and curing patients

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
Version 0.01 (2023-12-11 07:52:43.944000)

updates: Antengene initiates Phase I study of ATG-031 monoclonal antibody

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
Version 0.0 (2023-11-20 07:26:21.646000)

updates:

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔